A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients

Inclusion criteria

• Histological or cytological diagnosis of inoperable stage IIIB/IV non-squamous NSCLC
• At least one measurable lesion (RECIST criteria)
• Life expectancy > 3 months
• ECOG performance status 0-2
• Adequate hematologic function: WBC ≥ 3.0×109 /L，ANC ≥ 1.5×109 /L，Hb ≥ 90 g/L，PLT ≥ 100×109 /L
• Adequate renal, hepatic and coagulation function
• Written informed consent

Exclusion criteria

• With uncontrollable malignant pleural effusion or ascites
• Thoracic or abdominal surgery within 28 days prior to study entry
• History of cerebral stroke or TIA within 6 months prior to study entry
• With uncontrollable hypertension, hypertensive emergency or hypertensive encephalopathy
• Arrhythmia in need of antiarrhythmic treatment, history of angina pectoris, myocardial infarction, myocardial ischemia or congestive heart failure (> NYHA class II)
• With serious infection (> NCI CTC grade 2)
• Gastrointestinal perforation, fistula formation, and/or intra-abdominal abscess within 6 months prior to study entry
• Symptomatic brain metastases
• Patient who has epilepsy
• History of HIV infection or chronic hepatitis B or C
• Allergic to any of the study drugs
• Pregnant or lactating women